
Lipid metabolism in cancer progression and therapeutic strategies
Author(s) -
Fu Yan,
Zou Tiantian,
Shen Xiaotian,
Nelson Peter J.,
Li Jiahui,
Wu Chao,
Yang Jimeng,
Zheng Yan,
Bruns Christiane,
Zhao Yue,
Qin Lunxiu,
Dong Qiongzhu
Publication year - 2021
Publication title -
medcomm
Language(s) - English
Resource type - Journals
ISSN - 2688-2663
DOI - 10.1002/mco2.27
Subject(s) - lipid metabolism , tumor microenvironment , cancer cell , cancer , biology , tumor progression , context (archaeology) , lipid droplet , lipid signaling , cancer research , microbiology and biotechnology , biochemistry , receptor , paleontology , genetics
Dysregulated lipid metabolism represents an important metabolic alteration in cancer. Fatty acids, cholesterol, and phospholipid are the three most prevalent lipids that act as energy producers, signaling molecules, and source material for the biogenesis of cell membranes. The enhanced synthesis, storage, and uptake of lipids contribute to cancer progression. The rewiring of lipid metabolism in cancer has been linked to the activation of oncogenic signaling pathways and cross talk with the tumor microenvironment. The resulting activity favors the survival and proliferation of tumor cells in the harsh conditions within the tumor. Lipid metabolism also plays a vital role in tumor immunogenicity via effects on the function of the noncancer cells within the tumor microenvironment, especially immune‐associated cells. Targeting altered lipid metabolism pathways has shown potential as a promising anticancer therapy. Here, we review recent evidence implicating the contribution of lipid metabolic reprogramming in cancer to cancer progression, and discuss the molecular mechanisms underlying lipid metabolism rewiring in cancer, and potential therapeutic strategies directed toward lipid metabolism in cancer. This review sheds new light to fully understanding of the role of lipid metabolic reprogramming in the context of cancer and provides valuable clues on therapeutic strategies targeting lipid metabolism in cancer.